Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 25 July 2008:
Vol. 321. no. 5888, pp. 530 - 532
DOI: 10.1126/science.1161000
Prev | Table of Contents | Next

Perspective

HIV Vaccine Research: The Way Forward

Anthony S. Fauci,1* Margaret I. Johnston,1 Carl W. Dieffenbach,1 Dennis R. Burton,2 Scott M. Hammer,3 James A. Hoxie,4 Malcolm Martin,1 Julie Overbaugh,5 David I. Watkins,6 Adel Mahmoud,7 Warner C. Greene8

The need to broaden research directed at answering fundamental questions in HIV vaccine discovery through laboratory, nonhuman primate (NHP), and clinical research has recently been emphasized. In addition, the importance of attracting and retaining young researchers, developing better NHP models, and more closely linking NHP and clinical research is being stressed. In an era of a level budget for biomedical research at the U.S. National Institutes of Health (NIH), HIV/AIDS vaccine research efforts will need to be carefully prioritized such that resources to energize HIV vaccine discovery can be identified. This article summarizes progress and challenges in HIV vaccine research, the priorities arising from a recent summit at NIAID, and the actions needed, some already under way, to address those priorities.

1 National Institute of Allergy and Infectious Diseases, National Institutes of Health, 31 Center Drive, Bethesda, MD 20892, USA.
2 Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
3 Division of Infectious Diseases, Columbia University Medical Center, New York, NY 10032, USA.
4 Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
5 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
6 Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53711, USA.
7 Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
8 Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, CA 94158, USA.

* To whom correspondence should be addressed. E-mail: afauci{at}niaid.nih.gov

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Investing To Meet The Scientific Challenges Of HIV/AIDS.
A. S. Fauci and G. K. Folkers (2009)
Health Aff. 28, 1629-1641
   Abstract »    Full Text »    PDF »
A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies.
R. Pejchal, J. S. Gach, F. M. Brunel, R. M. Cardoso, R. L. Stanfield, P. E. Dawson, D. R. Burton, M. B. Zwick, and I. A. Wilson (2009)
J. Virol. 83, 8451-8462
   Abstract »    Full Text »    PDF »
Simian Immunodeficiency Virus SIVrcm, a Unique CCR2-Tropic Virus, Selectively Depletes Memory CD4+ T Cells in Pigtailed Macaques through Expanded Coreceptor Usage In Vivo.
R. Gautam, T. Gaufin, I. Butler, A. Gautam, M. Barnes, D. Mandell, M. Pattison, C. Tatum, J. Macfarland, C. Monjure, et al. (2009)
J. Virol. 83, 7894-7908
   Abstract »    Full Text »    PDF »
HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection.
M. Bonsignori, M. A. Moody, R. J. Parks, T. M. Holl, G. Kelsoe, C. B. Hicks, N. Vandergrift, G. D. Tomaras, and B. F. Haynes (2009)
J. Immunol. 183, 2708-2717
   Abstract »    Full Text »    PDF »
Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies.
S. M. O'Rourke, B. Schweighardt, W. G. Scott, T. Wrin, D. P. A. J. Fonseca, F. Sinangil, and P. W. Berman (2009)
J. Virol. 83, 7728-7738
   Abstract »    Full Text »    PDF »
Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human Trials.
R. A. Koup, L. Lamoreaux, D. Zarkowsky, R. T. Bailer, C. R. King, J. G. D. Gall, D. E. Brough, B. S. Graham, and M. Roederer (2009)
J. Virol. 83, 6318-6322
   Abstract »    Full Text »    PDF »
Comparison of Human and Rhesus Macaque T-Cell Responses Elicited by Boosting with NYVAC Encoding Human Immunodeficiency Virus Type 1 Clade C Immunogens.
P. Mooij, S. S. Balla-Jhagjhoorsingh, N. Beenhakker, P. van Haaften, I. Baak, I. G. Nieuwenhuis, S. Heidari, H. Wolf, M.-J. Frachette, K. Bieler, et al. (2009)
J. Virol. 83, 5881-5889
   Abstract »    Full Text »    PDF »
Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain.
L. Wu, T. Zhou, Z.-y. Yang, K. Svehla, S. O'Dell, M. K. Louder, L. Xu, J. R. Mascola, D. R. Burton, J. A. Hoxie, et al. (2009)
J. Virol. 83, 5077-5086
   Abstract »    Full Text »    PDF »
Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection.
Y. Guan, M. M. Sajadi, R. Kamin-Lewis, T. R. Fouts, A. Dimitrov, Z. Zhang, R. R. Redfield, A. L. DeVico, R. C. Gallo, and G. K. Lewis (2009)
PNAS 106, 3952-3957
   Abstract »    Full Text »    PDF »
An HIV Vaccine -- Challenges and Prospects.
M. I. Johnston and A. S. Fauci (2008)
N. Engl. J. Med. 359, 888-890
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)